Replies to post #108519 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

1. Request pre-IND meeting with the FDA

2. Submit IND to the FDA

3. Obtain IND approval

4. Start enrolment for the Phase 2b PD LID clinical trial in the USA

5. Submit Phase 2b design to EMEA



6. Obtain agreement on Phase 2b trial design with EMEA

7. Start enrolment for the Phase 2b PD LID clinical trial in Europe

"We are very pleased that our Eltoprazine program has progressed so rapidly under the direction of Dr. Keywood and Dr. Lowe," said Gerald E. Commissiong. "The initiation of the Phase 2b trial in PD LID will mark a major milestone for Amarantus. We expect to be in the clinic for this important indication by early 2015. PD LID represents a significant unmet medical need for Parkinson's disease patients."

There you go, it says early 2015, not 2014 as it does earlier in the same release. ALL of the things in that list take time, more time than is claimed in this release.

LOL, LMAO, again

GC just confirmed what I had been telling you. They did not include the IRB approval. That does not happen overnight either.

I am really belly laughing about this. now a chortle. I may need to call 911.